Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer

B. E. P. J. Vriens, M. J. B. Aarts, B. de Vries, S. M. van Gastel, J. Wals, T. J. Smilde, L. J. C. van Warmerdam, M. de Boer, D. J. van Spronsen, G. F. Borm, V. C. G. Tjan-Heijnen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)3102-3110
JournalEuropean Journal of Cancer
Volume49
Issue number15
DOIs
Publication statusPublished - Oct 2013

Keywords

  • Breast cancer
  • Cyclophosphamide
  • Docetaxel
  • Doxorubicin
  • Neoadjuvant chemotherapy

Cite this

Vriens, B. E. P. J., Aarts, M. J. B., de Vries, B., van Gastel, S. M., Wals, J., Smilde, T. J., van Warmerdam, L. J. C., de Boer, M., van Spronsen, D. J., Borm, G. F., & Tjan-Heijnen, V. C. G. (2013). Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. European Journal of Cancer, 49(15), 3102-3110. https://doi.org/10.1016/j.ejca.2013.06.012